News

Pfizer has announced positive topline results from their phase 3 clinical study of giroctocogene fitelparvovec, the company’s investigational hemophilia A gene therapy. …

These new medical-based webinars will speak to key topics relevant to the care of patients with inherited bleeding disorders. NBDF is excited…

Learn about Gene Therapy for Hemophilia with NBDF’s new resource collection. Find answers, research, and support. The National Bleeding Disorders Foundation (NBDF) is…

The National Bleeding Disorders Foundation (NBDF) is pleased to announce a new enduring and accredited educational activity available to healthcare providers. “Exploring…

Camp is an unforgettable experience for anyone fortunate enough to participate. Just one week each summer can give you memories that will…

BioMarin recently announced that they will be changing the scope of their efforts to manufacture and market their gene therapy product ROCTAVIAN.™…

by: Patricia Inácio, PhD | July 9, 2024 Hemgenix, the first approved hemophilia B gene therapy, was administered to two patients in France, marking the first time…

Gene therapy is a welcome treatment for patients, which has been anticipated for decades. But how do parents and patients discuss this…

NBDF’s National Youth Leadership Institute (NYLI) provides 18-24 year olds in the bleeding disorders community with leadership opportunities to encourage personal growth,…

A globe-trotting college traveler shares advice for traveling safely. Having a bleeding disorder shouldn’t keep you from seeing the world. Just ask…

While post-traumatic stress disorder is commonly connected with soldiers, people battling chronic illnesses can have it, too. Here’s how to identify the…

As we enter the “dog days” of summer with high temperatures and heat weighing folks down throughout much of the US, it’s…

The National Bleeding Disorders Foundation (NBDF) announces the THRIVE campaign to raise awareness and educate on living healthily with bleeding disorders. The…

Pfizer recently provided new clinical trial updates for their investigational therapy marstacimab. The data was presented last month at the 2024 annual meeting…

In an NBDF interview, Bill Robie, Senior Director of Government Relations, highlighted the ongoing challenges of living with von Willebrand disease. In…

by: Patrizia Cavazzoni, MD, Director, Center for Drug Evaluation and Research and Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and…

Do you need an HTC? A new HTC? Do you need to find one when you travel across the US? Check out the…

GLHF’s annual Wisconsin Bleeding Disorders Conference, for people and families living with a bleeding disorder, was held June 7-9 at the Kalahari…

Gene therapy research continues to evolve. As more information becomes available, the below may help you better understand gene therapy and shared…

Hemophilia truth time: hemophilia is a shared experience—affecting family, friends, and loved ones.  In a global survey of more than 2700 participants,…

Discover how the European Rare & Inhibitor Network (ERIN) is breaking barriers and advancing inclusivity for those with inherited bleeding disorders. This…

Even as therapies for hemophilia have expanded and improved, the issue of not following treatment regimens as directed remains a major point…

A researcher of disparities in hemophilia care discusses her findings and what’s still left to learn. by:  James Langford In the early…

Last year as a community we raised $76,437!  This year’s goal is $78,000 and we need your help to get there! Check…